Concepedia

Konstantin Dobrenkov

KD

19

Publications

972

Citations

15

H-Index

2005

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Royal North Shore Hospital

The University of Sydney

Melanoma Institute Australia

Konstantin Dobrenkov is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and immunology.

Top concepts

Publications per year

2005–2022

19

Publications

19

T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

Matthias T. Stephan, Vladimir Ponomarev, Renier J. Brentjens et al. · Nature Medicine · 2007 · 289 citations

, , +13

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Konstantin Dobrenkov, Irina Ostrovnaya, Jessie Gu et al. · Pediatric Blood & Cancer · 2016 · 140 citations · Full text

Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging

Konstantin Dobrenkov, Malgorzata Olszewska, Yury Likar et al. · Journal of Nuclear Medicine · 2008 · 88 citations · Full text

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov et al. · Cancer · 2020 · 65 citations · Full text

A New Pyrimidine-Specific Reporter Gene: A Mutated Human Deoxycytidine Kinase Suitable for PET During Treatment with Acycloguanosine-Based Cytotoxic Drugs

Yury Likar, Juan Zurita, Konstantin Dobrenkov et al. · Journal of Nuclear Medicine · 2010 · 61 citations · Full text

Rows per page

1–5 of 19